Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
NCT06096909
Summary
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.
Eligibility
Inclusion Criteria: * Patients aged 18 to 75 years; * clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ; * undergoing PCI * baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina. Exclusion Criteria: * Severe heart failure (Killip III or IV) or cardiogenic shock; * Previous hemorrhagic cerebrovascular disease history; * Uncontrolled or recurrent arrhythmic events; * poorly controlled hypertension; * Severe hepatic and renal insufficiency (ALT/AST\> 3 times upper limit of normal, eGFR\<30 ml/kg/1.73m2, or ongoing dialysis) or creatine kinase elevation\>5 times upper limit of normal * malignant tumor; * Intolerance to statins or cholesterol absorption inhibitors; * Intolerance to injections; * Life expectancy \<1 year; * poor compliance.
Conditions4
Interventions3
Related trials
- Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography — First Affiliated Hospital of Xinjiang Medical University
- Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS) — Yun Dai Chen
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. — Jinghui Wang
- Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer — Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer — Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06096909